The management of membranous nephropathy-an update

Basit Öğe Kaydı
dc.contributor.authorCaravaca-Fontan, Fernando
dc.contributor.authorFernandez-Juarez, Gema M.
dc.contributor.authorFloege, Juergen
dc.contributor.authorGoumenos, Dimitrios
dc.contributor.authorKronbichler, Andreas
dc.contributor.authorTurkmen, Kultigin
dc.contributor.authorvan Kooten, Cees
dc.date.accessioned2024-02-23T14:21:01Z
dc.date.available2024-02-23T14:21:01Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractIn recent decades, several important advances have taken place in the understanding of the pathogenesis underlying membranous nephropathy (MN) that have sparked renewed interest in its management. Four landmark trials in MN and a fifth clinical trial-which was a pilot study-have been published in recent years. The results from some of these trials have had a significant impact on the recommendations included in the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) Guideline for the Management of Glomerular Diseases, representing a significant step forward compared with the previous guideline in several aspects, including diagnosis, disease monitoring and treatment strategies. However, considering the rapidly evolving advances in the knowledge of MN and the recent publication of the STARMEN and RI-CYCLO trials, several recommendations contained in the guideline warrant updates. This article provides a perspective of the Immunonephrology Working Group of the European Renal Association regarding the management of MN in native kidneys of adult patients.en_US
dc.description.sponsorshipERAen_US
dc.description.sponsorshipThis article was written on behalf of the European Renal Association (ERA) IWG, which is an official body of the ERA. The IWG receives financial and logistic support from the ERA. G.F.J. and F.C.F. belong to the Spanish Renal Research Network (REDinREN; RD12/0021/0029).en_US
dc.identifier.doi10.1093/ndt/gfab316
dc.identifier.endpage1042en_US
dc.identifier.issn0931-0509
dc.identifier.issn1460-2385
dc.identifier.issue6en_US
dc.identifier.pmid34748001en_US
dc.identifier.scopus2-s2.0-85131018498en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1033en_US
dc.identifier.urihttps://doi.org/10.1093/ndt/gfab316
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13417
dc.identifier.volume37en_US
dc.identifier.wosWOS:000767450600001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofNephrology Dialysis Transplantationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCalcineurin Inhibitorsen_US
dc.subjectCyclophosphamideen_US
dc.subjectMembranous Nephropathyen_US
dc.subjectRemissionen_US
dc.subjectRituximaben_US
dc.titleThe management of membranous nephropathy-an updateen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu